Nasdaq-listed Anixa Biosciences board approves purchase of Bitcoin as reserve asset
Anixa Biosciences, a Nasdaq-listed company, has approved the purchase of Bitcoin as a reserve asset. The company also reiterated its ongoing stock buyback plan. Amit Kumar, CEO of the company, stated that the decision regarding Bitcoin is another way of prudent financial management and can achieve higher shareholder value. Anixa Biosciences is a biotechnology company focused on the treatment and prevention of cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Crypto Loan Carnival round 26: Borrow USDT, USDC to enjoy an APR discount of up to 40%
Crypto Loan Carnival round 26: Borrow USDT, USDC to enjoy an APR discount of up to 40%
Announcement on the increase of borrowing limit coefficients for Bitget spot margin VIP levels
Bitget x DGRAM Carnival: Grab a share of 49,500,000 DGRAM
